Celanese Plunges to $1.35B Loss on Massive Charges, Sales Dip

Ticker: CE · Form: 10-Q · Filed: 2025-11-07T00:00:00.000Z

Sentiment: bearish

Topics: Chemicals, Specialty Materials, Net Loss, Asset Impairment, Q3 Earnings, SEC Filing, Financial Performance

Related Tickers: CE, DD, LYB, EMN

TL;DR

**Celanese is bleeding cash, with a $1.35 billion loss this quarter; get out now before it gets worse.**

AI Summary

Celanese Corp reported a significant net loss of $1,353 million for the three months ended September 30, 2025, a stark contrast to the net earnings of $117 million in the same period of 2024. This substantial decline was primarily driven by a massive increase in 'Other (charges) gains, net,' which surged to a charge of $1,491 million in Q3 2025 from $61 million in Q3 2024. Net sales also decreased by 8.6%, falling to $2,419 million from $2,648 million year-over-year. For the nine months ended September 30, 2025, the company recorded a net loss of $1,173 million, compared to net earnings of $388 million in the prior year, with net sales dropping to $7,340 million from $7,910 million. Operating profit swung from a gain of $245 million in Q3 2024 to a loss of $1,275 million in Q3 2025. The company also reported asset impairments of $1,486 million for the nine months ended September 30, 2025, a substantial increase from $39 million in the prior year, contributing significantly to the net loss.

Why It Matters

This filing reveals a dramatic downturn for Celanese, with a net loss of $1,353 million in Q3 2025, primarily due to substantial 'other charges.' This performance is a major red flag for investors, indicating potential underlying issues or significant one-time events impacting profitability. Employees might face uncertainty given the company's financial strain, while customers could see impacts on product availability or pricing if operational adjustments are made. In the competitive chemical and specialty materials market, this significant loss could weaken Celanese's position against rivals like DuPont or LyondellBasell, potentially affecting its ability to invest in R&D or expand market share.

Risk Assessment

Risk Level: high — The risk level is high due to the dramatic swing from a net profit of $117 million in Q3 2024 to a net loss of $1,353 million in Q3 2025. This is primarily driven by a massive $1,491 million 'Other (charges) gains, net' in Q3 2025, compared to only $61 million in Q3 2024, and $1,486 million in asset impairments for the nine months ended September 30, 2025. These figures indicate significant operational or asset valuation challenges.

Analyst Insight

Investors should immediately re-evaluate their position in Celanese, considering the substantial net loss and the significant 'other charges' and asset impairments. A deeper dive into the nature of these charges is crucial, but the current financial trajectory suggests a strong sell signal or at least a hold until more clarity emerges on the company's ability to reverse these losses.

Financial Highlights

revenue
$2,419M
total Debt
$11,655M
net Income
($1,353M)
eps
($12.39)
gross Margin
21.5%
cash Position
$1,440M
revenue Growth
-8.6%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Sales$2,419M-8.6%

Key Numbers

Key Players & Entities

FAQ

Why did Celanese Corporation report a net loss in Q3 2025?

Celanese Corporation reported a net loss of $1,353 million for the three months ended September 30, 2025, primarily due to a substantial increase in 'Other (charges) gains, net' to $1,491 million, compared to only $61 million in the same period of 2024.

How did Celanese's net sales change in Q3 2025 compared to last year?

Celanese's net sales decreased by 8.6% in Q3 2025, falling to $2,419 million from $2,648 million for the three months ended September 30, 2024.

What was the impact of asset impairments on Celanese's financial results?

Asset impairments significantly impacted Celanese's financial results, totaling $1,486 million for the nine months ended September 30, 2025, a substantial increase from $39 million in the prior year, contributing to the overall net loss.

What is the operating profit (loss) for Celanese in Q3 2025?

Celanese reported an operating loss of $1,275 million for the three months ended September 30, 2025, a significant reversal from an operating profit of $245 million in the same period of 2024.

How has Celanese's long-term debt changed?

Celanese's long-term debt, net of unamortized deferred financing costs, increased to $11,655 million as of September 30, 2025, from $11,078 million as of December 31, 2024.

What are the key risks highlighted in Celanese's 10-Q filing?

While the specific 'Risk Factors' section is not provided in the excerpt, the significant net loss of $1,353 million, the $1,491 million in 'Other (charges) gains, net,' and $1,486 million in asset impairments strongly indicate high financial and operational risks for Celanese.

What is Celanese's cash position as of September 30, 2025?

As of September 30, 2025, Celanese Corporation had cash and cash equivalents of $1,440 million, an increase from $962 million at the beginning of the period on December 31, 2024.

What is the basic earnings (loss) per common share for Celanese in Q3 2025?

The basic earnings (loss) per common share for Celanese in Q3 2025 was ($12.39), a substantial decrease from $1.03 in the three months ended September 30, 2024.

What is the purpose of the 'Other (charges) gains, net' line item in Celanese's income statement?

The 'Other (charges) gains, net' line item captures various non-operating income and expenses, which in Q3 2025 included a significant charge of $1,491 million, indicating substantial non-recurring or unusual financial events impacting Celanese's profitability.

How does Celanese's Q3 2025 performance affect its overall year-to-date results?

Celanese's Q3 2025 performance significantly impacted its year-to-date results, leading to a net loss of $1,173 million for the nine months ended September 30, 2025, a sharp decline from net earnings of $388 million in the same period of 2024.

Risk Factors

Industry Context

Celanese operates in the chemicals industry, which is cyclical and sensitive to global economic conditions, raw material costs, and demand from end-use markets like automotive, construction, and consumer goods. The current environment appears challenging, with declining sales and significant charges impacting profitability across the sector.

Regulatory Implications

While this 10-Q does not detail specific new regulatory issues, companies in the chemical sector are subject to environmental, health, and safety regulations. Significant charges or impairments could attract scrutiny regarding asset valuation and risk management practices.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Other (charges) gains, net
This line item includes various non-operating income and expense items that are not part of the company's core business operations. It can include restructuring costs, legal settlements, gains or losses on asset sales, and other miscellaneous items. (A substantial charge of $1,491 million in Q3 2025 significantly impacted net income, making it a critical factor in understanding the company's loss.)
Asset Impairments
A reduction in the carrying value of an asset on the balance sheet when its fair value falls below its book value. This typically occurs when an asset is no longer expected to generate sufficient future economic benefits. (The $1,486 million in asset impairments for the nine months of 2025 is a major contributor to the company's net loss and signals potential overvaluation of assets or a decline in their future utility.)
Operating Profit (Loss)
This metric represents the profit or loss generated from a company's core business operations before accounting for interest, taxes, and other non-operating items. (The swing from a $245 million profit in Q3 2024 to a $1,275 million loss in Q3 2025 highlights a severe deterioration in the company's operational performance.)
Diluted EPS
Earnings per share (EPS) calculated using the weighted average number of outstanding common shares, including the dilutive effect of all potential common shares (such as stock options and convertible securities). (The drastic drop in diluted EPS from $1.03 in Q3 2024 to ($12.39) in Q3 2025 directly reflects the significant net loss and is a key indicator for investors.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Celanese Corp has experienced a dramatic financial downturn. Net sales decreased by 8.6% to $2,419 million, and the company swung from a net profit of $117 million to a substantial net loss of $1,353 million. This was primarily driven by a massive increase in 'Other (charges) gains, net' to $1,491 million and significant asset impairments totaling $1,486 million for the nine-month period, compared to minimal amounts in the prior year. Consequently, diluted EPS plummeted from $1.03 to ($12.39).

Filing Stats: 4,701 words · 19 min read · ~16 pages · Grade level 17.3 · Accepted 2025-11-07 16:41:32

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 a) Unaudited Interim Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 3 b) Unaudited Interim Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025 and 2024 4 c) Unaudited Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 d) Unaudited Interim Consolidated Statements of Equity for the three and nine months ended September 30, 2025 and 2024 6 e) Unaudited Interim Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 8 f) Notes to the Unaudited Interim Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 55 Item 4.

Controls and Procedures

Controls and Procedures 55

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 56 Item 1A.

Risk Factors

Risk Factors 56 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 56 Item 3. Defaults Upon Senior Securities 56 Item 4. Mine Safety Disclosures 56 Item 5. Other Information 56 Item 6. Exhibits 57

Signatures

Signatures 58 2 Table of Contents

Financial Statements

Item 1. Financial Statements CELANESE CORPORATION AND SUBSIDIARIES UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 (In $ millions, except share and per share data) Net sales 2,419 2,648 7,340 7,910 Cost of sales ( 1,898 ) ( 2,029 ) ( 5,811 ) ( 6,100 ) Gross profit 521 619 1,529 1,810 Selling, general and administrative expenses ( 231 ) ( 248 ) ( 676 ) ( 770 ) Amortization of intangible assets ( 42 ) ( 40 ) ( 124 ) ( 119 ) Research and development expenses ( 31 ) ( 32 ) ( 93 ) ( 99 ) Other (charges) gains, net ( 1,491 ) ( 61 ) ( 1,542 ) ( 123 ) Foreign exchange gain (loss), net 2 10 29 12 Gain (loss) on disposition of businesses and assets, net ( 3 ) ( 3 ) ( 2 ) ( 12 ) Operating profit (loss) ( 1,275 ) 245 ( 879 ) 699 Equity in net earnings (loss) of affiliates 39 51 90 157 Non-operating pension and other postretirement employee benefit (expense) income 2 3 5 7 Interest expense ( 177 ) ( 169 ) ( 524 ) ( 512 ) Refinancing expense — — ( 32 ) — Interest income 7 5 18 28 Dividend income - equity investments 40 30 82 95 Other income (expense), net 4 15 7 40 Earnings (loss) from continuing operations before tax ( 1,360 ) 180 ( 1,233 ) 514 Income tax (provision) benefit 7 ( 61 ) 75 ( 123 ) Earnings (loss) from continuing operations ( 1,353 ) 119 ( 1,158 ) 391 Earnings (loss) from operation of discontinued operations — ( 3 ) ( 16 ) ( 4 ) Income tax (provision) benefit from discontinued operations — 1 1 1 Earnings (loss) from discontinued operations — ( 2 ) ( 15 ) ( 3 ) Net earnings (loss) ( 1,353 ) 117 ( 1,173 ) 388 Net (earnings) loss attributable to noncontrolling interests ( 4 ) ( 4 ) ( 11 ) ( 5 ) Net earnings (loss) attributable to Celanese Corporation ( 1,357 ) 113 ( 1,184 ) 383 Amounts attributable to Celanese Corporation Earnings (loss) from continuing operations ( 1,357 ) 115 ( 1,169 ) 386 Earnings (loss) from discontinued operations — ( 2

View on Read The Filing